“CRISPR” is the word in the headline that signals that the piece is going to be about gene editing. Doc Gumshoe did not want to put that word – actually, it’s not really a word, but an acronym – in the title of this piece because gene editing is a whole lot more than […]
Articles
When we’re trying to fight against an adversary that is as strong and full of tricks as cancer, what we need to do is look for points of vulnerability – Achilles heels. We all remember, of course, that the mother of Achilles dipped him in the River Styx when he was a tiny boy, […]
Putting the name of this imperious disease in the title of my homily places a weighty responsibility on me. Who am I to attempt to put forth relevant information and sensible opinions on this topic, the mere mention of which makes most normal folk distinctly uneasy? But I probably pay more attention to […]
Every now and then a reader sends in a question about one of the stock ideas teased by dividend.com, which is a service that looks for, you guessed it, dividend paying stocks. Their standard “tease” is that they send around some hints about the latest stock they’ve added to one of their “best” lists, but […]
[ed. note: Michael Jorrin, who I call Doc Gumshoe, is a longtime medical writer (not a doctor) who writes for us about medicine and health a couple times a month. He has agreed to our trading and disclosure restrictions, but does not generally write directly about investment ideas. His ideas, thoughts and words are his […]
I wrote about Louis Navellier’s “solar monopoly” pitch a little while ago, but there was a also a cancer-fighting stock teased in that ad… and a few folks have been asking about that second stock, so I’ll see what we can do to get the Thinkolator on the case. Here’s a bit of the ad: […]
[ed. note: Michael Jorrin, who I dubbed “Doc Gumshoe” years ago, is a longtime medical writer (not a doctor) who writes for us a couple times a month about health issues and trends. He does not typically write about specific investment opportunities, but has agreed to our trading restrictions… as with all of our authors, […]
[Ed. Note: Dr. KSS writes about medicine and biotech stocks for the Irregulars. He has agreed to our trading restrictions, and his words and opinions are his own. You can find his bio and his past articles on his Stock Gumshoe page.] “The universe (which others call the Library) is composed of an indefinite and […]
[Dr. KSS writes about medicine and biotech stocks for the Irregulars. He has agreed to our trade restrictions, chooses his own topics, and his words and opinions are his own. You can see all his past articles and recent comments here.] The State of Things is a classy 1982 Wim Wenders film in which a film […]
[Ed. Note: Dr. KSS writes about medicine and biotech stocks for the Irregulars. He has agreed to our trading restrictions, choses his own topics, and his words and opinions are his own. You can see his past columns and most recent comments on his Stock Gumshoe page.] We first presented Gilead ($GILD) as a long idea […]
Everybody’s got to deviate from the norm. —Rush John Galsworthy wrote that the beginning and endings of human undertakings are untidy. It was never more so than in the early days of HCV, a mere 20 years ago, when a plague first called “non-A non-B hepatitis” began vexing people, progressively scarring their livers and behaving […]
[Ed. Note: Dr. KSS writes about medicine and biotech stocks for the Irregulars. He chooses his own topics, and his words and opinions are his own. His bio, past articles, and most recent comments can be seen here. Enjoy!] OUT of the night that covers me, Black as the Pit from pole to pole, I thank […]
[Ed. Note: Dr. KSS writes for the Irregulars about medicine and biotech stocks. He choses his own topics, and his words and opinions are his own. He has agreed to our trading restrictions. Enjoy!] In his smoky baritone, singer Stuart Staples of British midlands musical act Tindersticks is bemoaning how he suspects the woman he […]
Gumshoe BioDimSum II: Corralling the “A” Biotechs Plus a New Long Selection[Ed. Note: Dr. KSS writes for our Irregulars about medicine and biotech stocks. As always, he has agreed our trading restrictions, and his words and opinions are his own. You can find all of his previous articles here. And now, for some dim sum….] Greetings Irregulars, and welcome to Stock Gumshoe’s festive second BioDimSum shindig, a periodic round-up […]
[ed note: Michael Jorrin, who I like to call “Doc Gumshoe”, is a longtime medical writer (not a doctor) who shares his thoughts with us from time to time, generally on non-financial topics in health and medicine (as today, though, he mentions a couple publicly traded companies). His words and opinions are his own.] The […]
[ed note: Michael Jorrin is a longtime medical writer (not a doctor) who covers health and medical topics and trends for our readers, generally without an investment thesis. His words are his own, enjoy!] In the Doc Gumshoe blog about cancer that appeared in June of 2013 (you can check it out here), I commented […]
[ed note: Dr. KSS is a paid contributor to Stock Gumshoe who writes about biotech stocks for (and discusses them with) the Irregulars. He chooses his own topics, and his words and opinions are his alone. Enjoy!] Greetings fellow Irregulars! You’ve all been waiting for it….our first-ever annual ceremony in which we look back on […]
[Ed. Note: Dr. KSS writes about medicine and biotech stocks for the Irregulars. He has agreed to our trading restrictions, chooses his own topics, and his words and opinions are his own. His previous columns can be found here. Enjoy!] Every New Year, a friend and I flew to Boston. She’d gone to medical school […]
We’ve got a good teaser to solve today, but first — a quick plea: This will be our final week of “Gumshoe Gives Back” this year — we will be donating at least half of all the membership contributions received through the rest of this week (until the end of the day on Friday, 12/12) […]
In his tearjerker “Sisters of Mercy,” Leonard Cohen sings, I’ve been where you’re hanging and think I can see how you’re pinned. Although I am less inclined to bash the FDA than many, it has recently let modern medical practice place many patients in an undesirable situation. What if there was a very powerful drug, […]
Immunotherapy for cancer has been in the news quite a bit in recent years, with several drugs making an impact on the worst cancers and giving some real hope for future advancement — not a small thing for a basic medical strategy that’s been tested and tweaked for 125 years now by folks following in […]
[ed note: Michael Jorrin, a medical writer who we have dubbed “Doc Gumshoe” (he’s not a doctor), shares his thoughts with us once or twice a month — what follows is his latest missive, the words and opinions below are his alone.] I didn’t plan it this way, but the timing of this Doc Gumshoe […]
[Ed. Note: Dr. KSS writes about medicine and biotech stocks for the Irregulars. His words and opinions are his own.] In A History of New York, Washington Irving opens chapter VIII thus: ”In which the author and reader…fall into a very grave and instructive discourse.” This may prove to be a more unleavened column than […]
[Ed. Note: Here is the latest contribution from Dr. KSS, who writes for the Irregulars about medicine and biomedical stocks. As always, he has agreed to our trading restrictions and his words and thoughts are his own.] The Belle of the Everglades How To Profit From The Cure First of Two Parts Of the many […]
[Ed. Note: Here is our second installment from Dr. KSS, formerly known as “karmaswimswami” in Gumshoe discussion threads. Dr. KSS has agreed to our trading and disclosure restrictions, and he’s not offering you personal investment or medical advice. As with all of our columnists, we don’t assign topics or opinions and do just a bit of light […]
[ed note: We feature the musings of our favorite health and medicine writer, Michael Jorrin, a couple times a month, and we’ve taken the liberty of calling him “Doc Gumshoe” (he’s not a doctor). You’ll find no stock picks in his pieces, but hopefully will get plenty of insight into the medical matters he explains […]
[ed note: Another piece from “Doc Gumshoe” today — Michael Jorrin is not a doctor, he’s a longtime medical writer who we love because he explains diseases, treatments, and health controversies in a way that makes sense. The words and opinions shared below are his alone. If you’re curious about whether rheumatoid arthritis matters to […]
I’ve got a handful of updates for you, including one on a stock that I bought yesterday and a few other notes about recent quarterly reports from stocks I follow, but first … a teaser to solve … When I wrote about Marc Lichtenfeld’s pitch for “Spread Trusts” yesterday, I promised to also try to […]
As promised, we’re following up with the rest of the picks that Stephen Leeb (sorry, Dr. Stephen Leeb) is pitching as his “MCR” Plan. If you missed our first entry as we began demystifying this particular ad, you can see it here — the short version is, he’s touting dividend paying stocks in the medical […]
We use cookies on this site to enhance your user experience. By clicking any link on this page you are giving your consent for us to set cookies.
More Info
Comments
I find Matthew Carr to be a very good stock picker. As a Chairman's Circle member I receive all of his newsletters. Here...
This ad is still dated March, 2019, but it's also still circulating and I'm getting questions about it pretty regularly ...
Sounds like this is the Oxford MedMen tease, covered here: https://www.stockgumshoe.com/reviews/strategic-trends-investo...
Hey Trooper, who are you?, Matthew Carr, or Oxford Club ghost? Your post appears to be a copy of Matthew Carrs' teaser....
Sean is no longer with this newsletter; he is now with Weiss and a big name there. While I liked him, I think the ratin...
The V Score formula 100-[((F4QPE+TTE)/TTE)-1]*50 presented by Matthew Carr does not match his calculations! It appears t...
Travis, have you seem the tease by Matthew Carr (The Oxford Club) of the "Silicon Valley's Next Big Thing"? He says you ...
I have had very good results with Oxford, especially through Mark's recommendations and those of Alex Green and Matthew ...
What is the 'M index'being pushed by Matthew Carr with the Oxford Club??...
I fell for it. Set aside a trading account just for this newsletter. Lost 25% in one year. Cancelled subscription toda...
Hi again Jim Google "Matthew Carr Emerging Trends" Mike...
Q. Has Travis responded about this offer on the "Prime Strategy" from Matthew Carr? I didn't see a response--did I miss...